Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03187769 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
NCT03187769 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 426 participants.
The verdict
NCT03187769, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
Study Summary
This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness
Interventions
- DRUG Olanzapine
- DRUG ALKS 3831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2022-01-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03187769
The ClinicalTrials.gov registry entry for NCT03187769 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT03187769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03187769 about?
NCT03187769 is a clinical study titled "Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder". This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness
What is the current status of trial NCT03187769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2017-06-08. Estimated completion is 2022-01-03.
What interventions are being tested in trial NCT03187769?
The interventions under investigation include: Olanzapine (DRUG), ALKS 3831 (DRUG).
Who is sponsoring clinical trial NCT03187769?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.